The BCL3 Knockout HT29 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal cell population featuring targeted disruption of the BCL3 gene within the HT29 human colorectal adenocarcinoma cell line, offering a versatile loss-of-function model for dissecting BCL3-mediated biological processes. This heterogeneous knockout pool, generated through non-clonal gene editing, avoids biases associated with single-cell cloning and more faithfully represents the genetic variability encountered in tumor cell populations, enabling robust investigation of collective BCL3 ablation effects in a carcinoma-relevant context.
HT29 cells, originally isolated from a 44-year-old female with colorectal adenocarcinoma, are a widely characterized adherent epithelial model that displays microvilli and tight junctions, and retains the ability to undergo enterocytic or mucin-secreting differentiation. These cells faithfully recapitulate key features of the intestinal epithelium, including polarity and barrier function, and are extensively employed to study colorectal tumor biology, drug responsiveness, and the mechanistic links between inflammation and carcinogenesis. The use of HT29 as the parental background ensures that the BCL3 knockout retains these differentiated epithelial traits, allowing studies of gene function within a physiologically pertinent colorectal adenocarcinoma setting.
BCL3 operates as a transcriptional coactivator that modulates gene expression predominantly by binding to NF-??B p50/p52 homodimers, thereby governing cell proliferation, apoptosis, and immune responses. Its activity is induced by upstream stimuli such as TNF??, IL?1??, LPS, and CD40 ligand, and is further regulated by STAT3, while it interacts with key partners including NFKB1, NFKB2, HDAC1, HDAC3, and COPS5. BCL3 directly promotes the transcription of critical downstream effectors like CCND1 (cyclin D1), MYC, BCL2, MMP9, BIRC5 (survivin), and SNAI2, which collectively drive cell cycle progression, survival, and invasion. The coactivator integrates signals from NF???B, Wnt/???catenin, JAK/STAT, and PI3K/AKT pathways, with components such as IKBKB, CHUK, NFKBIA, CTNNB1, and RELA acting as central mediators. CRISPR/Cas9-mediated disruption of BCL3 abrogates p50/p52-dependent transcriptional activation, leading to diminished expression of pro?proliferative and anti?apoptotic genes and attenuating the tumorigenic potential of HT29 cells.
Within the HT29 colorectal cancer context, BCL3 knockout disrupts NF???B?driven transcriptional programs that sustain malignancy, resulting in reduced cyclin D1 and Bcl?2 production, impaired proliferation, and heightened apoptotic susceptibility. This genetic perturbation also dampens crosstalk with Wnt/???catenin and STAT3 pathways, reflecting mechanisms that underlie colorectal cancer progression and drug resistance. Thus, the knockout cells serve as a powerful system to elucidate BCL3??s role in linking chronic inflammation to tumorigenesis and to test therapeutic interventions targeting NF???B coactivator functions in solid tumors.
Researchers can apply these polyclonal BCL3 knockout cells to a broad set of functional assays, including Western blot and RT?qPCR validation of target gene modulation, MTT/CCK?8 proliferation assays, Annexin V/PI apoptosis analyses, wound healing and Transwell migration/invasion studies, and NF???B luciferase reporter assays to quantify transcriptional output. They are also suitable for co?immunoprecipitation experiments exploring BCL3 interactomes and xenograft tumor growth models for in vivo evaluation of tumorigenicity and chemosensitivity. Further applications encompass NF???B signaling dynamics, drug resistance mechanisms, and the interplay between inflammatory cues and oncogenic pathways in colorectal cancer. For additional technical details, please contact Ascent Research.
